In solid-phase peptide synthesis (SPPS) campaigns for injectable peptide APIs, EDC.HCl is introduced as a water-soluble carbodiimide to activate the carboxylic acid terminus of Fmoc-protected amino acids before on-resin amide bond formation. The process requires anhydrous N,N-dimethylformamide with residual water below 0.05% w/w; resin substitution is typically controlled between 0.32 mmol/g and 0.56 mmol/g for low-aggregation peptide sequences. Addition ratio: Fmoc-amino acid 3.0–4.0 molar eq, EDC.HCl 3.0–4.0 molar eq, HOBt·H₂O 3.0–4.0 molar eq, and N,N-diisopropylethylamine 6.0–8.0 molar eq relative to resin-bound free amine. Activation is performed at 2–8 °C for 5–10 min, followed by coupling at 20–25 °C for 45–60 min. On production-scale automated peptide synthesizers with jacketed glass columns, the dominant failure mode is resin-bed channeling when free water rises above 0.1% w/w; channeling reduces coupling efficiency and produces deletion peptides that are difficult to separate by preparative C18 chromatography. Fmoc deprotection with 20% v/v piperidine in DMF is monitored at 301 nm; a decline in deprotection UV area below the predicted value indicates incomplete terminal deprotection and requires extended dwell time or a second deprotection. Cleavage from the resin is conducted with TFA/H₂O/triisopropylsilane 95:2.5:2.5 v/v for 2 h at 25 °C; the crude peptide is precipitated in cold methyl tert-butyl ether at -20 °C, dissolved in aqueous acetonitrile, and purified on preparative reversed-phase HPLC columns (C18, 10 µm, 250 mm × 50 mm) using a mobile phase of acetonitrile/water with 0.1% v/v TFA. Salt exchange to acetate and lyophilization with a shelf ramp from -40 °C to 25 °C at 0.5 °C/min yields the peptide API as a lyophilized powder. Industry compliance standards include ICH Q7 for API GMP, ICH Q3C residual solvent limits, ICH Q3D elemental impurities, and 21 CFR 210/211 where the peptide enters finished dosage manufacturing. Residual EDC.HCl is consumed during the coupling step; its N-acylurea derivative is purged during preparative HPLC. Terminal finished products are sterile lyophilized peptide injections, prefilled pen cartridges, and vials. EDC.HCl stock solutions in DMF must be used within 4 h at 2–8 °C; prolonged storage produces N-acylurea adducts that are difficult to purge from the final peptide powder.

What Process Parameters Govern Amide Bond Formation During Solution-Phase Fragment Condensation for Oral Dosage Forms?

Control of the activation edge in solution-phase fragment condensation for oral peptide mimetics and small-molecule amide APIs is achieved at pH 5.5–6.5 in mixed aqueous-organic solvents such as ethyl acetate/THF or acetonitrile/water. EDC.HCl is charged at 1.0–1.2 molar eq relative to the carboxylic acid fragment, with HOBt·H₂O at 1.0–1.2 molar eq to suppress N-acylurea rearrangement. The carboxyl component is pre-activated in a jacketed glass-lined reactor at 0–5 °C with N-methylmorpholine added to maintain 5.5–6.5; the amine fragment is then added as a solution while the batch is held under nitrogen. The reaction mixture is warmed to 20–25 °C and stirred for 6–18 h. In-process UPLC is performed at 210 nm and 254 nm; the batch is released for workup when residual acid fragment is ≤ 0.5 area%. On a 500 L glass-lined reactor, cooling load is highest during the first 30 min after EDC.HCl addition because the O-acylisourea intermediate decomposes rapidly above 10 °C to the N-acylurea impurity. Workup consists of dilution with ethyl acetate, sequential washes with 5% w/v sodium bicarbonate, 0.5 N hydrochloric acid, and brine; the organic layer is dried over sodium sulfate and concentrated under reduced pressure. The API is crystallized from isopropanol/n-heptane and vacuum-dried at 40 °C until loss on drying is ≤ 0.5% w/w. Industry compliance standards include ICH Q3A for organic impurities, ICH Q3B for degradation products in finished dosage forms, ICH Q3C for residual solvents, ICH M7(R2) for mutagenic impurities, and 21 CFR 211 for finished oral dosage preparation. Terminal finished products are immediate-release tablets, hard gelatin capsules, and oral granules. Amine-based buffers such as Tris and glycine must be excluded during activation because they quench the carbodiimide before amide formation reaches target conversion.

In conjugate vaccine manufacturing, EDC.HCl is selected for carbodiimide-mediated conjugation of carboxylated capsular polysaccharides to carrier proteins because the reaction can be controlled in low-temperature aqueous buffers without organic co-solvents that denature carrier protein tertiary structure. The conjugation is performed in 0.1 M 2-(N-morpholino)ethanesulfonic acid at pH 6.0, with carrier protein and polysaccharide concentrations each between 5 mg/mL and 10 mg/mL. EDC.HCl is added to a final concentration of 5–10 mM; N-hydroxysulfosuccinimide is added to 10–20 mM, giving an EDC-to-active-ester molar ratio of 1:1 to 1:2. Activation of carboxyl groups on the polysaccharide or carrier protein is carried out at 2–8 °C for 4 h with continuous mixing in a single-use bioreactor bag or jacketed stainless vessel. The main process risk is excessive interprotein crosslinking when EDC.HCl exceeds 10 mM at pH 6.0; the resulting oligomerized carrier protein increases turbidity and reduces conjugate lot consistency measured by size-exclusion chromatography with multi-angle light scattering. Post-reaction quenching is performed with hydroxylamine at 10 mM; the conjugate is purified by tangential flow filtration on a 100 kDa regenerated cellulose membrane to remove unreacted EDC, NHS, and the isourea byproduct. The purified conjugate is sterile-filtered through 0.22 µm filters and filled into injectable vials or prefilled syringes. Industry compliance standards include 21 CFR 610.15 for biological product safety, WHO TRS Annex 2 for vaccine GMP, and ICH Q6B for specifications of biological products. Terminal finished products are injectable conjugate vaccines, including monovalent and multivalent presentations.

When a Long-Acting Injectable Requires Site-Selective PEGylation Without Compromising Receptor Binding

When covalent attachment of amino-functionalized polyethylene glycol to solvent-exposed protein carboxyl groups is required, EDC.HCl is used in a buffered aqueous process at pH 5.5–6.0 because carbodiimide activation proceeds rapidly enough to outcompete hydrolysis while minimizing amine protonation. The protein is formulated at 2–5 mg/mL in 50 mM MES; amino-PEG is charged at 10–20 molar eq relative to total protein carboxyl groups; EDC.HCl is added from a freshly prepared stock solution to a final concentration of 5–20 mM. The pH is maintained by a pH-stat with 0.1 N sodium hydroxide, and the reactor is held at 4 °C for 90–120 min. In pilot-scale bioprocessing, the reaction pH drifts downward by 0.3–0.5 pH units within the first 20 min because hydrochloric acid is released during EDC.HCl activation; failure to compensate leads to a drop below pH 5.0, where carboxyl groups become protonated and coupling efficiency declines. After the target reaction time, unreacted PEG and EDC byproducts are removed by tangential flow filtration on a 10 kDa membrane or by cation-exchange chromatography using SP Sepharose FF. The mono-PEGylated fraction is isolated by size-exclusion or cation-exchange chromatography; the pooled product is concentrated to 10–20 mg/mL, sterile-filtered, and lyophilized with sucrose/mannitol cryoprotectants. Industry compliance standards include ICH Q5E for comparability of biotechnological products, ICH Q6B for biological specifications, 21 CFR 601.20 for licensed biological products, and Ph. Eur. 5.1.1 for sterility where terminal sterilization is not feasible. Terminal finished products are long-acting injectable vials, prefilled syringes, and lyophilized powder for reconstitution.

Oral Polymer-Drug Conjugate Granule Manufacture and Residual Urea Control

Oral polymer-drug conjugate granule manufacture begins with the dissolution of a carboxylic acid-bearing polymer backbone in 0.1 M MES buffer at pH 5.0–5.5 and a polymer concentration of 5–10% w/v. Drug amine is added at 1.0–1.5 molar eq relative to polymer carboxylate groups; EDC.HCl is added at 2–5 molar eq relative to polymer carboxylate groups, with N-hydroxysuccinimide at 1.0–1.2 molar eq. The reaction is run at 4–8 °C for 6–12 h; the degree of amide substitution is monitored by 1H NMR or acid-base back-titration, with target substitution typically 10–25 mol%. The residual N-(3-dimethylaminopropyl)-N'-ethylurea is removed by diafiltration on a 5 kDa membrane using 10 volumes of water for injection. Incomplete urea removal leads to particulate formation upon reconstitution and fouling of downstream spray-dryer nozzles. The purified conjugate solution is spray-dried at inlet temperature 120–140 °C and outlet 70–80 °C to a powder with bulk density 0.35–0.60 g/cm³; the powder is subsequently wet-granulated with mannitol and croscarmellose sodium, dried at 40 °C, and filled into hard capsules or sachets. Industry compliance standards include ICH Q3A for unspecified impurities, ICH Q3C for residual solvents, ICH Q3D for elemental impurities, and USP <711> dissolution testing for the finished capsule. Terminal finished products are oral modified-release granules in capsules or sachets. Published industrial data for specific residual urea limits in polymer-drug conjugates is limited; acceptance limits should be derived from ICH Q3B thresholds and process validation studies.

A Different Control Strategy for Amide Bond Formation in Aqueous Peptide Drug Substance Finishing

Unlike organic-solvent SPPS, aqueous finishing of a peptide drug substance with EDC.HCl is limited to substrates that contain one free carboxyl group and no unprotected aspartate or glutamate side chains; otherwise intramolecular and intermolecular byproducts reduce purity. The peptide acid is dissolved in 50 mM sodium acetate at pH 4.8–5.2 and 4 °C; EDC.HCl is added at 0.5–1.0 molar eq relative to the peptide carboxyl group, and the reaction is quenched with 10 mM hydroxylamine after 30–60 min. The process stream is immediately loaded onto a strong anion-exchange column to remove unreacted acetic acid and urea byproduct; the product eluate is freeze-dried under a vacuum below 0.1 mbar with primary drying at -20 °C and secondary drying at 25 °C. This route is applied when coupling a small hydrophilic amine or alcohol to a peptide acid improves solubility or chemical stability before injection. Industry compliance standards include ICH Q7 for API manufacturing, ICH Q3C for residual solvents, and 21 CFR 211 for finished drug preparation. Terminal finished products are sterile injection powders and oral tablets.